Shenzhen Third People's Hospital

The Department of Infectious Diseases and Immunology at Shenzhen Third People's Hospital was established in May 2005. It is Shenzhen's designated department for admitting and treating patients with HIV/AIDS, a member department of the National Clinical Research Center for Infectious Diseases, a national, Guangdong provincial, and Shenzhen municipal key clinical discipline under development, the host institution of the Shenzhen HIV/AIDS Diagnosis and Treatment Quality Control Center, and a national clinical drug trial base specializing in HIV/AIDS. The department was among the earliest institutions in China to provide standardized antiretroviral therapy for HIV/AIDS and the prevention and treatment of opportunistic infections. It currently provides long-term antiretroviral follow-up for nearly 15,000 patients, and its treatment volume consistently ranks among the top three nationwide. The department comprises an inpatient ward, the Caring Clinic, an HIV Prevention and Post-Exposure Prophylaxis Clinic, an endoscopy suite, an operating room, the Caring Home, and an HIV/AIDS Clinical Research Laboratory, with 46 beds. Since 2019, it has been the first in China to complete 4 liver transplants with great success for patients with HIV/AIDS and hepatitis B who developed liver failure. Under Shenzhen's medical and health care Sanming Project, the department collaborates separately with the team of Professor Chen Zhiwei at the AIDS Institute of the University of Hong Kong and with Academician Wang Fusheng at the Fifth Medical Center of the Chinese People's Liberation Army. It also conducts multiple clinical and basic HIV/AIDS research projects with partners in the United States, France, Taiwan, China, and other countries and regions. Among these, its collaborative research with the University of Hong Kong on an innovative bivalent broadly neutralizing HIV antibody and a PD-1 vaccine has achieved interim results and attracted attention in China and abroad.

The Department of Infectious Diseases at Shenzhen Third People's Hospital was designated a Guangdong Provincial Specialty with Distinctive Strength in Infectious Diseases in 2008. In 2013, it was designated a National Key Clinical Specialty in Infectious Diseases, a Guangdong Provincial Key Specialty in Infectious Diseases, and a Shenzhen Municipal Key Discipline in Emerging Infectious Diseases. In 2015, through Shenzhen's Sanming Project, it successfully recruited the Zhejiang University Infectious Disease Diagnosis and Treatment Team led by Academician Li Lanjuan, one of China's foremost teams in infectious diseases, and received approval to become the Shenzhen Infectious Disease Treatment and Quality Control Center. Infectious Diseases Department 2 is also the main department responsible for the Shenzhen Center for Precision Medicine in Infectious Diseases. In 2017, the hospital's Department of Infectious Diseases ranked 18th nationwide in the Chinese Academy of Medical Sciences Science and Technology Influence Ranking. On February 26, 2018, Shenzhen Third People's Hospital, the Chinese Academy of Sciences Key Laboratory of Pathogenic Microbiology and Immunology, BGI, ZTE ICT, and Brazil's FIOCRUZ Foundation established the Center for Infectious Disease Prevention and Research, with the Department of Infectious Diseases serving as a principal implementing department. The department has 49 beds. It has strong technical capabilities and 27 medical staff, including 1 department director and 1 head nurse; its physicians include 1 chief physician, 1 associate chief physician, and 6 attending physicians, and its nursing staff includes 9 nurses-in-charge. The physicians include 1 person with a doctorate and 5 with master's degrees; the nursing staff includes 13 people with bachelor's degrees and 1 specialist nurse in liver disease. The department's team is a highly educated medical and nursing team distinguished by excellent professional quality, rigorous practice, extensive experience, strong technical competence, and dedication to its work.

The Department of Critical Care Medicine for Infectious Diseases at Shenzhen Third People's Hospital was established in 2003 and is currently led academically by Professor Wang Fuxiang. It has 12 physicians, including 4 with senior professional titles and 5 with intermediate professional titles; 3 hold doctorates and 5 hold master's degrees. It also has 18 nurses, including 1 associate chief nurse, 10 nurses-in-charge, and 3 senior nurses, with bachelor's degree holders accounting for 72%. The department currently has 38 beds and advanced negative-pressure respiratory isolation wards. It has an independent critical care resuscitation room equipped with electrocardiographic monitors, ventilators, and other essential emergency equipment. Its medical and nursing staff form a team of high professional quality, rigorous practice, extensive experience, strong technical competence, and dedication. The department bears primary responsibility for the prevention and treatment of infectious diseases in Shenzhen. Under the direct guidance of hospital leadership, it repeatedly achieved 'miracles' in rescuing patients with SARS and critical avian influenza and in preventing and treating influenza A (H1N1), hand, foot and mouth disease, and other infectious diseases. Its successful use of convalescent plasma to rescue critically ill patients with avian influenza reached an internationally advanced level. Its ability to handle public health emergencies successfully and prevent and control major infectious diseases has received high praise from principal leaders of the former Ministry of Health and the Guangdong Provincial Committee of the Communist Party of China. The department undertakes teaching for several universities and accepts medical interns from many universities in China each year; it hosts more interns from Shenzhen University Medical School and Guangdong Medical College than any other department in the hospital. Each year, it organizes multiple national, provincial, and municipal continuing education programs and leads multiple national, provincial, and municipal research projects.

The Department of Liver Oncology at Shenzhen Third People's Hospital was founded in 1996. After more than 20 years of dedicated development, it has built a highly qualified medical and nursing team with strong ethics, superb skills, and an excellent work style, as well as a complete structure comprising a specialty clinic, inpatient ward, pharmacology base, and laboratory. Integrating medical care, teaching, and research, it is a clinical discipline and a nationally recognized specialty brand in the field of liver disease. The department is the host institution of the Hepatology Professional Committee of the Shenzhen Association of Integrated Traditional Chinese and Western Medicine and the Shenzhen Multidisciplinary Liver Disease Alliance. It is also a member of the State Administration of Traditional Chinese Medicine's Cooperative Group for Severe Hepatitis and has become a clinical, teaching, and research center for the integrated traditional Chinese and Western medical diagnosis and treatment of liver disease in Shenzhen and surrounding areas. The department currently occupies one inpatient floor with 39 open beds and has a hepatology outpatient consulting room, a traditional Chinese medicine treatment room, a clinical drug trial base, and a traditional Chinese medicine laboratory. It uses distinctive therapies such as colon dialysis, iontophoresis, herbal fumigation, and topical applications, as well as traditional Chinese acupuncture and moxibustion techniques such as fire-dragon cupping, Panlong moxibustion, thread embedding, and floating-needle therapy. These services have created an advanced, comprehensive technical platform integrating traditional Chinese and Western medicine for diagnosing and treating all types of liver disease. The department has a strong talent pool, with a highly educated team that includes doctoral and master's degree holders and nurses with bachelor's degrees. It currently has 25 medical and nursing staff, including 2 with full-senior professional titles, 2 with associate-senior titles, 3 with doctorates, 5 with master's degrees, 2 members of national professional committees, and 8 members of provincial professional committees. The department focuses on diagnosing and treating various acute and chronic forms of hepatitis, hepatic fibrosis, cirrhosis, and liver cancer. Its integrated traditional Chinese and Western medical treatment of fatty liver disease, advanced cirrhosis, liver failure, severe jaundice, and precancerous liver lesions has reached an advanced level in China. It became a subcenter for integrated Chinese and Western medical clinical research projects on liver disease under the National Major Science and Technology Projects of the 11th, 12th, and 13th Five-Year Plans, including Chronic Severe Hepatitis, Chronic Hepatitis B, Chronic Hepatitis C, and Development of Clinical Research Bases for Viral Hepatitis. Over nearly 20 years, the department has trained 19 graduate students, including 6 doctoral and 13 master's students, and has received dozens of trainees in integrated Chinese and Western medicine for liver disease from Hong Kong, elsewhere in Shenzhen, and other cities. It has held more than 10 national, provincial, and municipal continuing education courses, training more than 1,200 liver disease professionals from across China, and has become an incubator for clinical talent in integrated Chinese and Western medicine for liver disease and a driving force for advances in medical technology in Shenzhen.

The Liver Disease Specialty at Shenzhen Third People's Hospital is a Shenzhen Municipal Key Specialty. Within it, the Department of Hepatitis and Cirrhosis was established in 2004 and is authorized to train master's degree students at the Second Affiliated Hospital of Southern University of Science and Technology. In 2007 and 2013, the department was respectively named a Shenzhen Youth Civilization Unit and a Guangdong Youth Civilization Unit. In 2014, the Shenzhen Women's Federation designated it a Women's Civilization Post, and in 2019, it received the title of Five-Star Department in the hospital's grading of departments for its Grade III Class A accreditation. The department currently has 8 physicians, including 3 with senior professional titles and 3 with intermediate titles; 1 holds a doctorate and 4 hold master's degrees. It also has 1 master's degree supervisor. It has 39 beds, receives more than 25,000 outpatient visits annually, and discharges nearly 1,000 patients each year. Distinguished by the use of evidence-based evaluation to guide treatment, the department has established a comprehensive liver disease diagnosis, treatment, and management system. It has a high level of expertise in diagnosing and treating many diseases, including various forms of acute and chronic hepatitis, such as hepatitis B, hepatitis C, drug-induced hepatitis, autoimmune hepatitis, alcoholic hepatitis, steatohepatitis, and hepatitis of unknown cause; cirrhosis; liver failure; liver cancer; hereditary metabolic liver disease; and liver disease accompanying other conditions, such as tuberculosis, diabetes, and pregnancy-related liver disease. It was also the first in Shenzhen to open a specialty clinic for difficult liver diseases in adolescents and children.

The Department of Complex and Critical Liver Diseases in the Liver Disease Medical Center at Shenzhen Third People's Hospital was established in May 1999. It is the lead department of Shenzhen's key specialty in liver disease, an authorized teaching site for doctoral and master's degrees in infectious disease internal medicine, and a postdoctoral research station of Southern University of Science and Technology. Department Director Professor Chen Jun is the discipline leader of Shenzhen's key specialty in liver disease, a Shenzhen local-level leading talent, a Shenzhen Category I practical clinical talent, and a doctoral supervisor at Southern University of Science and Technology. He received the Good Doctor of China title in 2020 from the National Health Commission and the Chinese Medical Doctor Association and holds positions in multiple national hepatology societies. Professor Dai Wei is chair of the Hepatology Committee of the Shenzhen Medical Association and formerly served as a member of the Hepatology Committee of the Chinese Medical Association; he has profound expertise in liver disease. The department currently has 10 physicians, including 3 with senior professional titles and 5 with intermediate professional titles; 1 holds a doctorate and 6 hold master's degrees. It also has 14 nurses, including 1 associate chief nurse and 4 nurses-in-charge. 50% of its physicians have undertaken advanced study at internationally renowned universities in the United States, the United Kingdom, and other countries. It is currently a medical team in Shenzhen with strong technical capabilities, equipment, and treatment methods for liver disease. In 1999, it was the first in China to provide artificial liver support therapy, including plasma exchange, hemoperfusion, hemodialysis, hemofiltration, plasma bilirubin adsorption, and the molecular adsorbent recirculating system. In 2019, it was designated a National Demonstration Center for Artificial Liver Support and Blood Purification. The ward has 39 beds. The department has distinctive expertise in diagnosing and treating viral hepatitis; drug-induced liver disease, including liver injury caused by Chinese herbal medicines and antituberculosis drugs; pediatric liver disease; hereditary metabolic liver disease; fatty liver disease, including alcoholic and nonalcoholic fatty liver disease; liver disease accompanying other conditions, such as tuberculosis, diabetes, and pregnancy; and toxic liver disease, especially poisonous mushroom poisoning.

Pulmonary Disease Department I is affiliated with the Shenzhen Clinical Research Center for Tuberculosis, the Guangdong Clinical Research Center for Tuberculosis, and the National Clinical Research Center for Infectious Diseases. It is a subspecialty of the National Key Clinical Specialty in Infectious Diseases, a Guangdong Provincial Key Clinical Specialty, a National Clinical Research Base for Tuberculosis Drugs, and a Shenzhen Municipal Key Clinical Specialty in Tuberculosis, and it is authorized to train master's degree students. The department is a designated facility for treating tuberculosis patients from Shenzhen and surrounding areas. It treats more than 1,300 patient visits involving all types of tuberculosis each year and undertakes tuberculosis research, teaching, clinical diagnosis, and treatment. Its distinctive strengths include integrated traditional Chinese and Western medical treatment of multidrug-resistant tuberculosis, pulmonary tuberculosis complicated by diabetes, therapeutic drug monitoring of antituberculosis medications for special populations, and the diagnosis and treatment of nontuberculous mycobacterial pulmonary disease. It has established a comprehensive system for tuberculosis diagnosis, treatment, follow-up, and cohort management. The department has a high level of clinical and research expertise in the diagnosis, treatment, and differential diagnosis of pulmonary tuberculosis, including newly treated, retreated, and multidrug-resistant tuberculosis; lymph-node tuberculosis; pediatric tuberculosis; tuberculous meningitis; genitourinary tuberculosis; intestinal tuberculosis; tuberculous peritonitis; nontuberculous mycobacterial disease; and many other conditions. It has 50 open beds and 8 physicians, including 1 chief physician, 3 associate chief physicians, 3 attending physicians, and 1 resident physician; 1 physician holds a doctorate and 5 hold master's degrees. Several staff members have undertaken advanced training at the Guangzhou Institute of Respiratory Health and Beijing Chest Hospital.

Pulmonary Disease Department II was established in 1985 and was the hospital's earliest tuberculosis ward. It is now part of the National Clinical Research Center for Infectious Diseases (Tuberculosis), a subspecialty of the National Key Clinical Specialty in Infectious Diseases, a National Clinical Research Base for Tuberculosis Drugs, a Shenzhen Municipal Key Clinical Specialty in Tuberculosis, the Shenzhen Clinical Research Center for Tuberculosis, and the Guangdong Clinical Research Center for Tuberculosis. The department has 47 beds. It specializes in diagnosing and treating multidrug-resistant pulmonary tuberculosis, tuberculous meningitis, and tuberculosis in special populations and has established a comprehensive tuberculosis diagnosis, treatment, and management program. It has a high level of clinical and research expertise in the diagnosis, treatment, and differential diagnosis of pediatric tuberculosis, reproductive-system tuberculosis, abdominal tuberculosis, nontuberculous mycobacterial disease, and many other conditions. Chief Physician and Professor Deng Guofang heads the department. It has 10 physicians, including 1 chief physician, 2 associate chief physicians, and 3 with intermediate professional titles; 2 hold doctorates and 7 hold master's degrees. It also has 21 nurses. The department hosts the annual South China Tuberculosis Forum, which has major influence and recognition nationwide. It also provides classroom teaching and clinical internships for medical students from several universities.